Ghrelin inhibits proliferation and increases T-type Ca 2+ channel expression in PC-3 human prostate carcinoma cells

Biochemical and Biophysical Research Communications

Volumn 403, Issue 1, 2010, Pages 24-29

  Díaz Lezama, Nundehui ^a   Hernández Elvira, Mariana ^a   Sandoval, Alejandro ^b   Monroy, Alma ^c   Felix, Ricardo ^c   Monjaraz, Eduardo ^a  

^a BENEMÉRITA UNIVERSIDAD AUTÓNOMA DE PUEBLA   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

Author keywords

Ca V3 channels; Ca 2+ channels; Ghrelin; Mibefradil; Pimozide; Prostate cancer

Indexed keywords

CALCIUM; CALCIUM CHANNEL T TYPE; GHRELIN;

APOPTOSIS; ARTICLE; CALCIUM CELL LEVEL; CARCINOMA CELL; CELL MEMBRANE; CELL PROLIFERATION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; UPREGULATION;

APOPTOSIS; CALCIUM CHANNELS, T-TYPE; CARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; GHRELIN; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 78649693668     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.10.100     Document Type: Article

References (21)

1. Kojima M., Hosoda H., Date Y., Nakazato M., Matsuo H., Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999, 402:656-660.
2. Kojima M., Hosoda H., Matsuo H., Kangawa K. Ghrelin: discovery of the natural endogenous ligand for the growth hormone secretagogue receptor. Trends Endocrinol. Metab. 2001, 12:118-122.
3. Nikolopoulos D., Theocharis S., Kouraklis G. Ghrelin: a potential therapeutic target for cancer. Regul. Pept. 2010, 163:7-17.
4. Jeffery P.L., Herington A.C., Chopin L.K. Expression and action of the growth hormone releasing peptide ghrelin and its receptor in prostate cancer cell lines. J. Endocrinol. 2002, 172:7-11.
5. Murata M., Okimura Y., Iida K., Matsumoto M., Sowa H., Kaji H., Kojima M., Kangawa K., Chihara K. Ghrelin modulates the downstream molecules of insulin signaling in hepatoma cells. J. Biol. Chem. 2002, 277:5667-5674.
6. Cassoni P., Papotti M., Catapano F., Ghè C., Deghenghi R., Ghigo E., Muccioli G. Specific binding sites for synthetic growth hormone secretagogues in non-tumoral and neoplastic human thyroid tissue. J. Endocrinol. 2000, 165:139-146.
7. Cassoni P., Papotti M., Ghè C., Catapano F., Sapino A., Graziani A., Deghenghi R., Reissmann T., Ghigo E., Muccioli G. Identification, characterization, and biological activity of specific receptors for natural (ghrelin) and synthetic growth hormone secretagogues and analogs in human breast carcinomas and cell lines. J. Clin. Endocrinol. Metab. 2001, 86:1738-1745.
8. Cassoni P., Ghé C., Marrocco T., Tarabra E., Allia E., Catapano F., Deghenghi R., Ghigo E., Papotti M., Muccioli G. Expression of ghrelin and biological activity of specific receptors for ghrelin and des-acyl ghrelin in human prostate neoplasms and related cell lines. Eur. J. Endocrinol. 2004, 150:173-184.
9. Ghè C., Cassoni P., Catapano F., Marrocco T., Deghenghi R., Ghigo E., Muccioli G., Papotti M. The antiproliferative effect of synthetic peptidyl GH secretagogues in human CALU-1 lung carcinoma cells. Endocrinology 2002, 143:484-491.
10. Yeh A.H., Jeffery P.L., Duncan R.P., Herington A.C., Chopin L.K. Ghrelin and a novel preproghrelin isoform are highly expressed in prostate cancer and ghrelin activates mitogen-activated protein kinase in prostate cancer. Clin. Cancer. Res. 2005, 11:8295-8303.
11. Grynkiewicz G., Poenie M., Tsien R.Y. A new generation of calcium indicators with greatly improved fluorescence properties. J. Biol. Chem. 1985, 260:3440-3450.
12. V3.1 channels by glucocorticoids. Cell. Mol. Neurobiol. 2009, 29:1265-1273.
13. Davenport A.P., Bonner T.I., Foord S.M., Harmar A.J., Neubig R.R., Pin J.P., Spedding M., Kojima M., Kangawa K. International union of pharmacology. LVI. Ghrelin receptor nomenclature, distribution, and function. Pharmacol. Rev. 2005, 57:541-546.
14. 2+-permeable cation channel by two different inducers of apoptosis in a human prostatic cancer cell line. J. Physiol. 1999, 517:95-107.
15. 2+ homeostasis and apoptotic resistance of neuroendocrine-differentiated prostate cancer cells. Cell. Death Differ. 2004, 11:321-330.
16. 2+ channels in GC somatotropes after long-term exposure to ghrelin and growth hormone releasing peptide-6. Cell. Mol. Neurobiol. 2008, 28:819-831.
17. Dominguez B., Felix R., Monjaraz E. Ghrelin and GHRP-6 enhance electrical and secretory activity in GC somatotropes. Biochem. Biophys. Res. Commun. 2007, 358:59-65.
18. 2+ levels regulate Bcl-xS and Bcl-xL expression in spermatogenic cells during apoptotic death. J. Biol. Chem. 2006, 281:2133-2143.
19. 2+ signaling, cell activation and cell survival in immune cells. Mol. Immunol. 2010, 47:640-648.
20. 2+ channels. J. Recept. Signal. Transduct. Res. 2005, 25:57-71.
21. Lee J.H., Daud A.N., Cribbs L.L., Lacerda A.E., Pereverzev A., Klöckner U., Schneider T., Perez-Reyes E. Cloning and expression of a novel member of the low voltage-activated T-type calcium channel family. J. Neurosci. 1999, 19:1912-1921.